Anti-RANKL Magnetic Beads Immunoprecipitation (IP) Kit

Temporarily not available outside of China.
Price:
Size:
Number:

Anti-RANKL 磁珠免疫沉淀(IP)试剂盒产品组分

Components Storage
Anti-RANKL Magnetic Beads1,3 2-8℃ for 12 months
NP40 Cell Lysis Buffer2 -20℃ for 12 months
5×TBST(pH7.4)  
1×TBST(pH7.4)  
ddH2O  
Alkaline Elution Buffer 2-8℃ for 12 months
Acidity Elution Buffer 2-8℃ for 12 months
Neutralization Buffer 2-8℃ for 12 months

【1】The IP KIT contains anti-RANKL magnetic Beads (2 mg/mL) in phosphate buffered saline (PBS, pH 7.4) with sodium azide (0.1%).

【2】Using NP-40 cell lysate buffer in the kit is required,otherwise,the magnetic beads may be precipitated.

【3】Shipping: Magnetic Beads kits are shipped at ambient temperature in which magnetic beads are provided in liquid buffer.

Anti-RANKL 磁珠免疫沉淀(IP)试剂盒产品描述

The Anti-RANKL magnetic Beads, conjugated with Anti-RANKL antibody, are used for immuneprecipitation (IP) of RANKL proteins which expressed in vitro expression systems. For IP, the beads are added to a sample containing RANKL proteins to form a bead-protein complex. The complex is removed from the solution manually using a magnetic separator. The bound RANKL proteins are dissociated from the magnetic beads using an elution buffer.

Anti-RANKL 磁珠免疫沉淀(IP)试剂盒抗体信息

抗体
Recombinant Anti-RANKL Antibody, Rabbit Monoclonal(11682-R101)
免疫原
Recombinant Human RANKL / OPGL / TNFSF11 / CD254 protein (Catalog#11682-HNCH)
交叉反应
Human RANKL / OPGL / TNFSF11 / CD254
来源
Monoclonal Human Rabbit IgG
制备方法
This antibody was obtained from a rabbit immunized with purified, recombinant Human RANKL / OPGL / TNFSF11 / CD254 (rh RANKL / OPGL / TNFSF11 / CD254; Catalog#11682-HNCH; O14788-2; Gly63-Asp244).
应用
Immunoprecipitation (IP), Minimum Protein Purification

Anti-RANKL Magnetic Beads Immunoprecipitation (IP) Kit: 别称

Anti-CD254ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-hRANKL2ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-ODFALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-OPGLALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-OPTB2ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-RANKLALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-sOdfALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-TRANCEALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit

RANKL 背景信息

Tumor necrosis factor ligand superfamily member 11, also known as Receptor activator of nuclear factor kappa-B ligand, Osteoprotegerin ligand, TNFSF11, RANKL, TRANCE, OPGL and CD254, is a single-pass type II membrane protein that belongs to the tumor necrosis factor family. The receptor activator of nuclear factor-kappaB ligand (RANKL), its cognate receptor RANK, and its natural decoy receptor osteoprotegerin have been identified as the final effector molecules of osteoclastic bone resorption. RANK and RANKL are key regulators of bone remodeling and regulate T cell/dendritic cell communications, and lymph node formation. Moreover, RANKL and RANK are expressed in mammary gland epithelial cells and control the development of a lactating mammary gland during pregnancy. Genetically, RANKL and RANK are essential for the development and activation of osteoclasts and bone loss in response to virtually all triggers tested. Inhibition of RANKL function via the natural decoy receptor osteoprotegerin (OPG, TNFRSF11B) prevents bone loss in postmenopausal osteoporosis and cancer metastases. Importantly, RANKL appears to be the pathogenetic principle that causes bone and cartilage destruction in arthritis. RANK-RANKL signaling not only activates a variety of downstream signaling pathways required for osteoclast development, but crosstalk with other signaling pathways also fine-tunes bone homeostasis both in normal physiology and disease. In addition, RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy.
全称
tumor necrosis factor (ligand) superfamily, member 11
研究领域
参考文献
  • Takayanagi H, et al. (2002) Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Res. 4 Suppl 3: S227-32.
  • Nakashima T, et al. (2003) RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol. 15(3): 280-7.
  • Schwarz EM, et al. (2007) Clinical development of anti-RANKL therapy. Arthritis Res Ther. 9 Suppl 1: S7.
  • Leibbrandt A, et al. (2008) RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci. 1143: 123-50.
添加购物车成功! 添加购物车失败!请再次尝试 正在更新购物车,请稍后 U.S.A.